CWI1-2
Based on 6 publication(s) in Google Scholar
CWI1-2 is an IGF2BP2 inhibitor that binds IGF2BP2 and inhibits its interaction with m6A-modified target transcripts, induces apoptosis and differentiation, and shows promising anti-leukemic effects.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 98.85%
- No. CAS: 2408590-36-1
- Fòrmula: C22H17Cl3N6O3
- Peso molecular:519.77
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Blood Cancer Compound Library
HY-L079
-
Cell Death Library
HY-L162
-
Anti-Hematopathy Compound Library
HY-L171
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) CWI1-2
More
Customer Validation & Images
-
Bio/Physico-chemical Assay
-
WB
-
Cell Imaging/Staining
-
WB
-
Cell Imaging/Staining
Actividad biológica
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| THP-1 | IC50 |
200 nM
Compound: 12; CW11-2
|
Antiproliferative activity against human THP-1 cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay
Antiproliferative activity against human THP-1 cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay
|
[PMID: 38382391] |
CWI1-2 (0-1 μM, 24 h) has good anti-leukemic efficacy[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MonoMac6, MOLM13
-
Concentration:0-1 μM
-
Incubation Time:24 h
-
Result:Induced significant cell differentiation and apoptosis in a concentration-dependent manner in IGF2BP2-high cells but not in IGF2BP2-low cells.
Reduced Gln uptake and impaired mitochondrial function, resulting in reduced ATP production in AML cells.
Significantly inhibited the colony-forming ability of MA9-induced leukemic mouse blasts and greatly impairs the self-renewal of LSC/LIC.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 2408590-36-1
-
Appearance Solid
-
Peso molecular 519.77
-
Fòrmula C22H17Cl3N6O3
-
Color Light yellow to yellow
-
SMILES
OC(C=C1)=C(C=C1Cl)/C=N/N=C(N/N=C\C(C=C2Cl)=C(C=C2)O)\N/N=C/C(C=C3Cl)=C(C=C3)O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
Targeting eEF1A reprograms translation and uncovers broad-spectrum antivirals against cap or m6A protein synthesis routes. [Abstract]2025 Feb 7;16(1):1087. PMID: 39920115
CWI1-2 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 7;16(1):1087. [Abstract]
IGF2BP2 inhibitor CWI1-2 (1-5 μM) reduced HIV-1 luciferase expression in Vero E6 cells.
-
J Adv Res
PAD4-mediated citrullination of IGF2BP2 stabilizes MCM mRNAs to drive intrahepatic cholangiocarcinoma progression. [Abstract]2026 Jun 5:S2090-1232(26)00460-1. PMID: 42250722 -
Int J Biol Sci
H3K27 Acetylation-driven IGF2BP2 Mutates during the Aging of MSCs, thereby Influencing Osteogenic Differentiation and Bone Aging. [Abstract]2026 Jan 1;22(1):142-160. PMID: 41362747
CWI1-2 purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2026 Jan 1;22(1):142-160. [Abstract]
CWI1-2 (1 μM; 48 h) significantly reduced protein levels of HMGA1 in senescent MSCs.
CWI1-2 purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2026 Jan 1;22(1):142-160. [Abstract]
CWI1-2 (1 μM; 48 h) alleviated senescence in MSCs, as evidenced by reduced SA-β-gal positivity.
CWI1-2 purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2026 Jan 1;22(1):142-160. [Abstract]
CWI1-2 (1 μM; 48 h) reduced senescence marker expression in MSCs.
CWI1-2 purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2026 Jan 1;22(1):142-160. [Abstract]
CWI1-2 (1 μM; 48 h) decreased the fluorescence intensity of IGF2BP2 and Hmga1 mRNA and reduced their co-localization in MCSs.
-
Cell Rep
The m6A reader IGF2BP2 promotes homologous recombination-mediated DNA repair by eliminating DNA-RNA hybrids. [Abstract]2025 Oct 15;44(10):116438. PMID: 41100254 -
Biochem Pharmacol
Chlorogenic acid promotes macrophage phagocytosis through the METTL3-SIRPA axis in an m6A-dependent manner for colon cancer therapy. [Abstract]2026 Jun 25:252:118198. PMID: 42349614 -
Solvente y solubilidad
DMSO : 100 mg/mL (192.39 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 1.25 mg/mL (2.40 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 1.25 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (278 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9239 mL | 9.6196 mL | 19.2393 mL | 48.0982 mL |
| 5 mM | 0.3848 mL | 1.9239 mL | 3.8479 mL | 9.6196 mL | |
| 10 mM | 0.1924 mL | 0.9620 mL | 1.9239 mL | 4.8098 mL | |
| 15 mM | 0.1283 mL | 0.6413 mL | 1.2826 mL | 3.2065 mL | |
| 20 mM | 0.0962 mL | 0.4810 mL | 0.9620 mL | 2.4049 mL | |
| 25 mM | 0.0770 mL | 0.3848 mL | 0.7696 mL | 1.9239 mL | |
| 30 mM | 0.0641 mL | 0.3207 mL | 0.6413 mL | 1.6033 mL | |
| 40 mM | 0.0481 mL | 0.2405 mL | 0.4810 mL | 1.2025 mL | |
| 50 mM | 0.0385 mL | 0.1924 mL | 0.3848 mL | 0.9620 mL | |
| 60 mM | 0.0321 mL | 0.1603 mL | 0.3207 mL | 0.8016 mL | |
| 80 mM | 0.0240 mL | 0.1202 mL | 0.2405 mL | 0.6012 mL | |
| 100 mM | 0.0192 mL | 0.0962 mL | 0.1924 mL | 0.4810 mL |
CWI1-2 Related Classifications
HY-153274 Related Classifications
Powered by Bioz